Behrens B C, Young R C, DeVita V T
Drugs. 1985 Oct;30(4):355-67. doi: 10.2165/00003495-198530040-00004.
The prognosis of patients with Hodgkin's disease has dramatically improved over the past few decades. Treatment with currently standard radiotherapy or combination chemotherapy programmes will result in durable complete remissions and probable cure in most patients. However, these programmes are intensive, technically demanding, and associated with a risk of certain acute side effects and long term complications which vary in nature and severity according to the specific therapy employed. The outlook for the few patients who do not achieve complete remission with induction therapy, or for those who later relapse (especially after complete remissions induced by chemotherapy), is less optimistic. Current trials of innovative induction and salvage therapies may lead to improved treatment approaches for such patients.
在过去几十年中，霍奇金淋巴瘤患者的预后有了显著改善。采用目前标准的放射治疗或联合化疗方案进行治疗，大多数患者会实现持久的完全缓解并有可能治愈。然而，这些方案强度大、技术要求高，且伴有某些急性副作用和长期并发症的风险，这些副作用和并发症的性质和严重程度会因所采用的具体治疗方法而有所不同。对于少数诱导治疗未达到完全缓解的患者，或那些后来复发的患者（尤其是化疗诱导完全缓解后复发的患者），前景则不太乐观。目前关于创新诱导和挽救治疗的试验可能会为这类患者带来改进的治疗方法。
